CAMBRIDGE, Mass., July 07, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, announced the granting of equity awards to a new employee under its 2025 Inducement Stock Incentive Plan. This grant, issued on July 1, 2025, includes non-statutory stock options to purchase 128,600 shares of the company's common stock at an exercise price of $0.32 per share, matching the closing price on the grant date. The stock options have a 10-year term, with a vesting schedule of 25% on the first anniversary of the employee's start date, and 6.25% vesting quarterly thereafter, contingent on continued employment with the company. The inducement grant adheres to the award agreements and the 2025 Inducement Stock Incentive Plan terms.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。